IONS250117C42500
- 0.10
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $67
Wells Fargo Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $77
Ionis Pharmaceuticals: Strategic Path to Cash Flow Positivity and Strong Pipeline Drive Buy Rating
Ionis Pharmaceuticals: Promising Pipeline and Strategic Shifts Drive Buy Rating
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $55
Ionis Pharmaceuticals: Hold Rating Amid Uncertainty in Future Financial Performance
Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51
Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $62
Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $51
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $59 to $67
Ionis Pharmaceuticals Analyst Ratings
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $75
TD Cowen Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $59
Raymond James Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $61
J.P. Morgan Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)
Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $62